Oramed Pharmaceuticals Inc.
ORMP
$2.33
$0.031.30%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -19.06M | 4.47M | 20.86M | 10.46M | 5.53M |
| Total Depreciation and Amortization | 193.00K | 215.00K | 217.00K | 215.00K | 196.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.26M | -15.33M | -25.51M | -14.39M | -13.32M |
| Change in Net Operating Assets | 3.20M | 2.73M | 2.92M | -2.51M | -2.70M |
| Cash from Operations | -8.41M | -7.92M | -1.51M | -6.22M | -10.30M |
| Capital Expenditure | -18.00K | -10.00K | -37.00K | -57.00K | -254.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 105.84M | 120.40M | 79.57M | -29.78M | -72.78M |
| Cash from Investing | 105.82M | 120.39M | 79.53M | -29.84M | -73.04M |
| Total Debt Issued | -- | 0.00 | 99.55M | 99.55M | 99.55M |
| Total Debt Repaid | -49.55M | -74.55M | -99.55M | -69.00M | -50.00M |
| Issuance of Common Stock | -- | 0.00 | 0.00 | 0.00 | 2.43M |
| Repurchase of Common Stock | -2.49M | -1.29M | -2.00K | -2.00K | -2.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -52.04M | -75.84M | -2.00K | 30.55M | 51.98M |
| Foreign Exchange rate Adjustments | -4.00K | 6.00K | -28.00K | -17.00K | -54.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 45.37M | 36.64M | 77.99M | -5.53M | -31.41M |